Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Systemic tumor regression in patients with indolent B cell lymphoma before vaccine (on left) and after vaccine. Photo: Joshua Brody/Mount Sinai Health System

Scientists announced a preliminary success in devising a cancer "vaccine" that was able to help prime the immune system to attack lymphoma cancer tumors in some patients, leading to a period of remission, according to a clinical study of 11 patients published in Nature Medicine Monday.

Why it matters: Indolent non-Hodgkin’s lymphomas (iNHLs) tend to be a slow-growing cancer that is incurable with standard therapy and poorly responsive to a newer type of treatment called checkpoint blockade. Scientists have been seeking ways to broaden the response of immunotherapy to more patients, and a therapeutic cancer vaccine is one option that's under consideration.

Background: There are many types of immune cells in the body, with dendritic and T-cells both playing powerful but distinct roles. Dendritic cells detect an infection or cancer cells and alert the T-cells to attack en masse.

  • But, cancer cells often elude discovery by the immune system for a variety of reasons.

This new type of treatment is designed to force the tumor to expose itself and trigger the immune response.

What they did: The trial, which began in 2013, tested a three-pronged attack as part of the treatment. The tests were done first in animals and then in 11 human patients, most of whom had iNHLs, says study author Joshua Brody, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai Hospital.

  • The treatment was injected into one of the tumor sites to spur the tumor to make a therapeutic "vaccine" that triggers the immune system.

How it works: Each of the 3 components in the treatment plays an important role, Brody says. Separately, each have shown modest improvements in patient outcomes, but together they show a stronger impact.

  • The components recruit dendritic cells to the tumor, and help the immune system identify the threat by activating the body's detection system. The ultimate goal is to have T-cells proliferating and spreading throughout the body to kill any cancer cells.

What they found: The mouse trial was robust and successful, while the trial in the human participants showed a strong response in some, but not all, patients.

  • The "vaccine was dramatically successful in some patients, with partial and complete remissions (of non-injected tumors) lasting for months to years," Brody says.
  • For non-responders, they found the patients still had developed new T-cells and their tumors had become responsive to a type of treatment called PD1 blockade, prompting a followup trial of the combined therapy.

What they're saying: Several experts who were not part of this study tell Axios it shows some promising results, but also caution that the study was small and only helped some of the patients.

  • James Rubenstein, professor in residence at UCSF's Department of Medicine, says this offers a roadmap for future research that emphasizes the potential strategic role of dendritic cells in new treatments. "This particular study is promising because of the incorporation of multiple strategies including the successful local recruitment of dendritic cells," he says.
  • Pavan Reddy, deputy director of the University of Michigan's Comprehensive Care Center, calls it an "exciting" study. But, he adds, "the human studies, while exciting, must be emphasized as preliminary. ... [I]t worked only in a few patients. Furthermore, indolent lymphomas typically progress slowly, so the quality and duration of the responses even from the limited responders will need to be assessed."

What's next: Based on the early success, the research team has already started a new clinical trial for patients with lymphoma, breast cancer and head/neck cancer that adds the fourth component — the PD1 blockade — in the hope of getting that last resistant set of patients to respond.

Go deeper

Updated 3 hours ago - World

In photos: Pope Francis spreads message of peace on first trip to Iraq

Pope Francis waving as he arrives near the ruins of the Syriac Catholic Church of the Immaculate Conception (al-Tahira-l-Kubra), in the old city of Iraq's northern Mosul on March 7. Photo: Vincenzo Pinto/AFP via Getty Images

Pope Francis was on Sunday visiting areas of northern Iraq once held by Islamic State militants.

Why it matters: This is the first-ever papal trip to Iraq. The purpose of Francis' four-day visit is largely intended to reassure the country's Christian minority, who were violently persecuted by ISIS, which controlled the region from 2014-2017.

Cuomo faces fresh misconduct allegations from former aides

New York Gov. Andrew Cuomo during a February press conference in New York City. Photo: Seth Wenig/Pool/AFP via Getty Images

The office of New York Gov. Andrew Cuomo (D) was on Saturday facing fresh accusations of misconduct against his staff, including further allegations of inappropriate behavior against two more women. His office denies the claims.

Driving the news: The Washington Post reported Cuomo allegedly embraced an aide when he led the U.S. Department of Housing and Urban Development and that two male staffers who worked for him in the governor's office accused him of routinely berating them "with explicit language."

In photos: Protesters rally for George Floyd ahead of Derek Chauvin's trial

Chaz Neal, a Redwing community activist, outside the Minnesota Governor's residence during a protest in support of George Floyd in St.Paul, Minnesota, on March 6. Photo: Kerem Yucel/AFP via Getty Images

Dozens of protesters were rallying outside the Minnesota governor's mansion in St Paul Saturday, urging justice for George Floyd ahead of former Minneapolis police officer Derek Chauvin's trial over the 46-year-old's death.

The big picture: Chauvin faces charges for second-degree murder and manslaughter over Floyd's death last May, which ignited massive nationwide and global protests against racism and for police reform. His trial is due to start this Monday, with jury selection procedures.